Scientists at the Institute of Brain and Intelligence, University of Sydney, Australia, recently published a new research result-a new vaccine in the scientific journal PLoS ONE (scientific journal PLoS ONE). This vaccine is expected to slow the progression of Alzheimer's disease and other dementia patients.
The study found that by binding this new vaccine to a target protein called tau, it prevented the formation of neurofibrillary tangles in the brains of mice with Alzheimer's disease. The early results of this trial are very good, which undoubtedly brings great hope to patients.
Alzheimer's disease and Parkinson's disease laboratory scientists said: The study first showed that this vaccine target to tau protein will have a blocking effect on the established disease-slow down the development of neurofibrillary tangles, Instead of removing the existing tangles, the precise mechanism of action it contains is still unclear.
Scientists have conducted clinical studies on vaccines against Alzheimer's diseased amyloid plaques for many years. Most vaccine research is conducted through animal models of disease formation and pre-onset. The majority of patients with Alzheimer's disease can only be diagnosed after symptoms appear.
Alzheimer's disease is a common progressive neurodegenerative disease that affects approximately 35 million people worldwide. This tau protein is also present in the symptoms of frontotemporal dementia. This disease is the second dementia in the population before the age of 65. As the population tends to age and the incidence of Alzheimer's disease rises, it is of great significance to carry out human studies of this vaccine.
The research team has collaborated with US pharmaceutical companies to develop vaccines suitable for humans. Although there is still a long way to go for human use, scientists are confident in the new vaccine.
Infared forehead thermometer,Forehead thermometers digital,Forehead thermometer strips
DongGuan Jinao Packaging Products Co., Ltd , https://www.jinaojewelrybox.com